What question did this study set out to answer?

To evaluate the effectiveness of AI-enabled whole-exome sequencing of plasma ctDNA for identifying biomarkers in advanced NSCLC.

March 19, 2026ESMO OpenOpen Access

81P AI-enabled platform for baseline plasma ctDNA whole-exome profiling to identify candidate biomarkers of immunotherapy outcomes in advanced driver-negative NSCLC

View Full Paper

Ask AI

Bookmark

To evaluate the effectiveness of AI-enabled whole-exome sequencing of plasma ctDNA for identifying biomarkers in advanced NSCLC.
Utilized an AI-enabled platform for whole-exome sequencing of plasma-derived ctDNA.
Analyzed genomic patterns to assess response to immunotherapy.
Focused on blood-based tumor mutational burden as a predictive biomarker.
Identified broader genomic patterns linked to immunotherapy outcomes.
Demonstrated inconsistencies in traditional blood-based tumor mutational burden effectiveness.
Showed potential for improved biomarker identification through AI analysis.

Implication

Analysis of blood-derived ctDNA identifies genomic markers in advanced NSCLC, suggesting improved immunotherapy outcomes.

Abstract

Predictive biomarkers for immune checkpoint inhibitors (ICIs) in advanced NSCLC remain imperfect. While blood-based tumour mutational burden (bTMB) is attractive, its performance is inconsistent. Whole-exome sequencing (WES) of plasma-derived ctDNA, analysed through an automated, AI-enabled platform (AIRGenomics), may reveal broader genomic patterns associated with response or resistance to immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Posado-Domínguez et al. (2026) studied this question.

synapsesocial.com/papers/69bb938e496e729e629817ee https://doi.org/10.1016/j.esmoop.2026.106388

View Full Paper

Ask AI

Bookmark

Implication

Analysis of blood-derived ctDNA identifies genomic markers in advanced NSCLC, suggesting improved immunotherapy outcomes.

81P AI-enabled platform for baseline plasma ctDNA whole-exome profiling to identify candidate biomarkers of immunotherapy outcomes in advanced driver-negative NSCLC

Key Points

Implication

Abstract

Discussion

Cite This Study

81P AI-enabled platform for baseline plasma ctDNA whole-exome profiling to identify candidate biomarkers of immunotherapy outcomes in advanced driver-negative NSCLC

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading